In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 inhibition in COVID-19 development and progression.
Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths / Strollo, R.; Maddaloni, E.; Dauriz, M.; Pedone, C.; Buzzetti, R.; Pozzilli, P.. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - 171:(2021). [10.1016/j.diabres.2020.108444]
Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths
Maddaloni E.;Buzzetti R.;
2021
Abstract
In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 inhibition in COVID-19 development and progression.| File | Dimensione | Formato | |
|---|---|---|---|
|
Strollo_DPP4-inhibitors_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
493.99 kB
Formato
Adobe PDF
|
493.99 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
